Heli Rajaniemi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Heli Rajaniemi has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
Kari Hemminki
Department of Biosciences at Novum Karolinska Institute 141 57 Novum Huddinge Sweden
3 shared publicationsEero Mäntylä
Department of Biosciences at Novum, Karolinska Institute, 14157 Huddinge, Sweden
2 shared publicationsB Lindahl
1 shared publicationB Moberger
1 shared publicationIlpo Rasanen
University of Helsinki, Department of Forensic Medicine, FIN-00014 Helsinki and
1 shared publicationK Hemminki
Department of Biosciences at Novum, Karolinska Institute, Huddinge, Sweden
1 shared publication
Latest Publications
- Open Access
- 1 February 1999
- Published by Oxford University Press (OUP) in Carcinogenesis
- Vol. 20 (2) , 305-309
Identification of the major tamoxifenDNA adducts in rat liver by mass spectroscopy
We present here the first mass spectroscopic (MS) identification of the main tamoxifen-induced DNA adducts in rat liver. The two main adducts were isolated by high-performance liquid chromatography (HPLC) and identified by MS, MS–MS and ultraviolet spectroscopy. Adduct 1 was the N-desmethyltamoxifen–deoxyguanosine adduct in which the α-position of the metabolite N-desmethyltamoxifen is linked covalently to the amino group of deoxyguanosine. Adduct 2 was confirmed to be the trans isomer of α-(N2-deoxyguanosinyl)tamoxifen, as previously suggested by co-chromatography.
- 1 February 1999
- Published by Oxford University Press (OUP) in Carcinogenesis
- Vol. 20 (2) , 305-309
Open AccessIdentification of the major tamoxifenDNA adducts in rat liver by mass spectroscopy
We present here the first mass spectroscopic (MS) identification of the main tamoxifen-induced DNA adducts in rat liver. The two main adducts were isolated by high-performance liquid chromatography (HPLC) and identified by MS, MS–MS and ultraviolet spectroscopy. Adduct 1 was the N-desmethyltamoxifen–deoxyguanosine adduct in which the α-position of the metabolite N-desmethyltamoxifen is linked covalently to the amino group of deoxyguanosine. Adduct 2 was confirmed to be the trans isomer of α-(N2-deoxyguanosinyl)tamoxifen, as previously suggested by co-chromatography.
- 1 December 1998
- Published by Elsevier in Toxicology Letters
- Vol. 102-103, 453-457
DNA binding of tamoxifen and its analogues: identification of the tamoxifen-DNA adducts in rat liver.
- 1 December 1998
- Published by Elsevier in Toxicology Letters
- Vol. 102-103, 453-457
DNA binding of tamoxifen and its analogues: identification of the tamoxifen-DNA adducts in rat liver.
- 1 May 1998
- Published by Elsevier in Chemico-Biological Interactions
- Vol. 113 (2) , 145-159
DNA adduct formation by tamoxifen and structurally-related compounds in rat liver
- 1 May 1998
- Published by Elsevier in Chemico-Biological Interactions
- Vol. 113 (2) , 145-159
DNA adduct formation by tamoxifen and structurally-related compounds in rat liver
- 1 October 1996
- Vol. 56 (19) , 4374-7
Tamoxifen-induced DNA adducts in endometrial samples from breast cancer patients.
Tamoxifen-induced DNA adducts were analyzed with the (32)P-postlabeling method using high-performance liquid chromatography (HPLC)-radioactivity detection from endometrial tissue of breast cancer patients and controls. Liver DNA from tamoxifen-treated rats was used as a positive standard. In blind analysis, five of the seven samples from tamoxifen-treated patients showed DNA adducts; none of the five controls were positive. The identity of the tamoxifen adduct was confirmed by using different chromatographic systems, isolating the HPLC fractions and running them on TLC, with or without spiked rat liver samples. The level of adducts in the treated patients was 2.7 adducts/10(9) nucleotides in the HPLC analysis.
- 1 October 1996
- Vol. 56 (19) , 4374-7
Tamoxifen-induced DNA adducts in endometrial samples from breast cancer patients.
Tamoxifen-induced DNA adducts were analyzed with the (32)P-postlabeling method using high-performance liquid chromatography (HPLC)-radioactivity detection from endometrial tissue of breast cancer patients and controls. Liver DNA from tamoxifen-treated rats was used as a positive standard. In blind analysis, five of the seven samples from tamoxifen-treated patients showed DNA adducts; none of the five controls were positive. The identity of the tamoxifen adduct was confirmed by using different chromatographic systems, isolating the HPLC fractions and running them on TLC, with or without spiked rat liver samples. The level of adducts in the treated patients was 2.7 adducts/10(9) nucleotides in the HPLC analysis.